Source-grounded facts extracted from Edgewise Therapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Edgewise Therapeutics, Inc. shareholders approved Advisory Vote on the Compensation of the Company's Named Executive Officers at the 2026-06-04 meeting.
“Proposal 3: Advisory Vote on the Compensation of the Company's Named Executive Officers For Against Abstain 87,055,111 3,491,326 577,257”
Edgewise Therapeutics, Inc. shareholders approved Ratification of the Appointment of Independent Registered Public Accounting Firm at the 2026-06-04 meeting.
“Proposal 2: Ratification of the Appointment of Independent Registered Public Accounting Firm For Against Abstain 99,637,228 1,123 578,031”
Edgewise Therapeutics, Inc. shareholders approved Election of three Class II Directors at the 2026-06-04 meeting.
“Proposal 1: Election of three Class II Directors Name of Director For Withheld Laura Brege 87,300,827 3,822,867 Badreddin Edris, Ph.D. 64,082,681 27,041,013 Jonathan Root, M.D. 59,213,781 31,909,913”
Edgewise Therapeutics, Inc. entered into Asset Purchase Agreement with Servier Pharmaceuticals LLC and Les Laboratoires Servier valued at $1.55 billion in cash at closing, plus potential milestone payments up to $1.1 billion (effective 2026-05-31).
“On June 1, 2026, Edgewise Therapeutics, Inc., (the “Company”) announced its entry into an Asset Purchase Agreement (the “Agreement”) with Servier Pharmaceuticals LLC and Les Laboratoires Servier (together, the “Buyers”) on May 31, 2026.”
Edgewise Therapeutics, Inc. reported financial results for first quarter of 2026.
“Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today reported financial results for the first quarter of 2026 and recent business highlights.”
Behrad Derakhshan changed role as Chief Operating Officer at Edgewise Therapeutics, Inc..
“On January 8, 2025, the Board of Directors (the “ Board ”) of Edgewise Therapeutics, Inc. (the “ Company ”) promoted Behrad Derakhshan, Ph.D. to the role of Chief Operating Officer of the Company, effective immediately.”
Edgewise Therapeutics, Inc. terminated Common Stock Sales Agreement with BofA Securities, Inc. (effective 2024-05-10).
“In connection with the Company's entry into the Sales Agreement, on May 10, 2024, the Company delivered written notice to BofA Securities to terminate the Prior Sales Agreement pursuant to Section 11(b) thereof.”
Edgewise Therapeutics, Inc. entered into Sales Agreement with Leerink Partners LLC valued at up to $175,000,000 (effective 2024-05-10).
“On May 10, 2024, Edgewise Therapeutics, Inc. (the "Company") entered into a Sales Agreement (the "Sales Agreement") with Leerink Partners LLC ("Leerink") under which the Company may offer and sell shares of the Company's common stock, par value $0.0001 per share (the "Common Stock"), having aggregate sales proceeds of up to $175,000,000 (the "Shares"), from time to time, through an "at the market offering" program under which Leerink will act as sales agent.”
Edgewise Therapeutics, Inc. reported financial results for first quarter of 2024.
“On May 9, 2024, Edgewise Therapeutics, Inc. issued a press release announcing its financial results for the first quarter ended March 31, 2024.”
Arlene Morris was appointed as Director at Edgewise Therapeutics, Inc..
“On May 6, 2024, the Board of Directors (the “Board”) of Edgewise Therapeutics, Inc. (the “Company”) appointed Arlene Morris to serve (i) as a Class I director, with a term expiring at the Company’s 2025 annual meeting of stockholders, (ii) as a member of the Audit Committee of the Board (the “Audit Committee”), and (iii) as a member of the Compensation Committee of the Board (the “Compensation Committee”), replacing Peter Thompson as a member of the Audit Committee and Compensation Committee.”
Edgewise Therapeutics, Inc. reported financial results for fourth quarter and full year ended December 31, 2023.
“On February 22, 2024, Edgewise Therapeutics, Inc. issued a press release announcing its financial results for the fourth quarter and full year ended December 31, 2023.”
Edgewise Therapeutics, Inc. entered into Underwriting Agreement with Leerink Partners LLC, as representative of the underwriters valued at approximately $240.0 million (effective 2024-01-19).
“On January 19, 2024, Edgewise Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC, as representative of the underwriters listed therein (the “Underwriters”), relating to the issuance and sale in an underwritten registered direct offering (the “Registered Direct Offering”) by the Company of 21,818,182 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), at an offering price of $11.00 per share. Gross proceeds from the Registered Direct Offering before deducting underwriting discounts and commissions and other offering expenses are expected to be approximately $240.0 million.”
Edgewise Therapeutics, Inc. reported financial results for third quarter ended September 30, 2023.
“On November 9, 2023, Edgewise Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the third quarter ended September 30, 2023.”
Edgewise Therapeutics, Inc. reported financial results for second quarter of 2023.
“Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative treatments for severe, genetic neuromuscular and cardiac disorders for which there is significant unmet medical need, today reported financial results for the second quarter of 2023 and recent business highlights.”
Edgewise Therapeutics, Inc. received a nasdaq deficiency notice notice regarding audit committee (rules 5605(c)(2), 5605(c)(4)).
“July 10, 2023, Edgewise Therapeutics, Inc. (the “Company”) received a notice (the “Notice”) from The Nasdaq Stock Market LLC (the “Nasdaq”) stating that, as a result of the resignation of Kenneth Harrison, Ph.D. (the “Director Resignation”) from the Board of Directors of the Company (the “Board”) and the Audit Committee of the Board (the “Audit Committee”), effective June 19, 2023 (as previously disclosed), the Company is no longer in compliance with the Nasdaq Listing Rule 5605, including the Nasdaq Listing Rule 5605(c)(2), which requires the Audit Committee to consist of at least three membe”
Kenneth Harrison resigned as Director at Edgewise Therapeutics, Inc..
“On June 19, 2023, Kenneth Harrison, Ph.D. informed the Board that he was resigning from the Board and all of its committees, effective on such date”
Edgewise Therapeutics, Inc. terminated Prior Sales Agreement with Cowen and Company, LLC valued at Terminated prior to any sales of Placement Shares (effective 2023-06-15).
“In connection with the Company’s entry into the Sales Agreement, on June 15, 2023, the Company delivered written notice to Cowen to terminate the Prior Sales Agreement pursuant to Section 11(b) thereof.”
Edgewise Therapeutics, Inc. entered into Sales Agreement with BofA Securities, Inc. valued at up to $125,000,000 (effective 2023-06-16).
“On June 16, 2023, Edgewise Therapeutics, Inc. (the “Company”) entered into a Sales Agreement (the “Sales Agreement”) with BofA Securities, Inc. (“BofA Securities”) under which the Company may offer and sell shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), having aggregate sales proceeds of up to $125,000,000 (the “Shares”), from time to time, through an “at the market offering” program under which BofA Securities will act as sales agent.”
Edgewise Therapeutics, Inc. shareholders approved Ratification of the Appointment of Independent Registered Public Accounting Firm at the 2023-06-09 meeting.
“Proposal 2 : Ratification of the Appointment of Independent Registered Public Accounting Firm For Against Abstain 59,989,284 2,555 219 The stockholders ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.”
Edgewise Therapeutics, Inc. shareholders approved Election of three Class II Directors at the 2023-06-09 meeting.
“Proposal 1: Election of three Class II Directors Name of Director For Withheld Broker Non-Votes Laura Brege 47,325,534 11,602,125 1,064,399 Badreddin Edris, Ph.D. 45,321,337 13,606,322 1,064,399 Jonathan Root, M.D. 45,595,269 13,332,390 1,064,399”
Edgewise Therapeutics, Inc. reported financial results for first quarter of 2023.
“Edgewise Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2023.”
Dr. Jonathan Fox was appointed as Director at Edgewise Therapeutics, Inc..
“On March 2, 2023, the Board of Directors (the “Board”) of Edgewise Therapeutics, Inc. (the “Company”) appointed Dr. Jonathan Fox to serve (i) as a Class III director, with a term expiring at the Company’s 2024 annual meeting of stockholders, and (ii) as a member of the Nominating and Corporate Governance Committee of the Board (the “Nominating Committee”).”
Edgewise Therapeutics, Inc. reported financial results for the third quarter ended September 30, 2022.
“On November 3, 2022, Edgewise Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the third quarter ended September 30, 2022.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.